Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling

The pathophysiology of pulmonary hypertension (PH) and heart failure (HF) includes fibrogenic remodeling associated with the loss of pulmonary arterial (PA) and cardiac compliance. We and others have previously identified transglutaminase 2 (TG2) as a participant in adverse fibrogenic remodeling. Ho...

Full description

Saved in:
Bibliographic Details
Published inThe FASEB journal Vol. 34; no. 1; p. 930
Main Authors Bhedi, Chinmayee D, Nasirova, Sabina, Toksoz, Deniz, Warburton, Rod R, Morine, Kevin J, Kapur, Navin K, Galper, Jonas B, Preston, Ioana R, Hill, Nicholas S, Fanburg, Barry L, Penumatsa, Krishna C
Format Journal Article
LanguageEnglish
Published United States 01.01.2020
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The pathophysiology of pulmonary hypertension (PH) and heart failure (HF) includes fibrogenic remodeling associated with the loss of pulmonary arterial (PA) and cardiac compliance. We and others have previously identified transglutaminase 2 (TG2) as a participant in adverse fibrogenic remodeling. However, little is known about the biologic mechanisms that regulate TG2 function. We examined physiological mouse models of experimental PH, HF, and type 1 diabetes that are associated with altered glucose metabolism/glycolysis and report here that TG2 expression and activity are elevated in pulmonary and cardiac tissues under all these conditions. We additionally used PA adventitial fibroblasts to test the hypothesis that TG2 is an intermediary between enhanced tissue glycolysis and fibrogenesis. Our in vitro results show that glycolytic enzymes and TG2 are upregulated in fibroblasts exposed to high glucose, which stimulates cellular glycolysis as measured by Seahorse analysis. We examined the relationship of TG2 to a terminal glycolytic enzyme, pyruvate kinase M2 (PKM2), and found that PKM2 regulates glucose-induced TG2 expression and activity as well as fibrogenesis. Our studies further show that TG2 inhibition blocks glucose-induced fibrogenesis and cell proliferation. Our findings support a novel role for glycolysis-mediated TG2 induction and tissue fibrosis associated with experimental PH, HF, and hyperglycemia.
ISSN:1530-6860
DOI:10.1096/fj.201902155R